Nanosphere (NSPH +9.7%) gets a boost from an initiation at Canaccord with a Buy rating and a $5...
Nanosphere (NSPH +9.7%) gets a boost from an initiation at Canaccord with a Buy rating and a $5 price target. Canaccord says NSPH is poised to capture a big chunk of the molecular diagnostics business after revamping its strategic approach last year ago to focus on blood stream infections. The company garnered FDA approval of its Gram-Positive Blood Culture Nucleic Acid Test in June 2012, and has become an early leader in the rapid detection of sepsis, which kills around 200K Americans annually and infects over 750K.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Jan 2, 2013)
at MarketWatch.com (Jul 9, 2012)
at MarketWatch.com (Jul 3, 2012)
at CNBC.com (Jun 22, 2011)
at MarketWatch.com (Jun 21, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs